IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
START TREMFYANTTM: ACR20 RESPONSE AT WEEK 24 AFTER JUST 4 INJECTIONS1-3

P<0.0001 vs placebo.

*The same patients may not have responded at each timepoint.

ACR20 responses in DISCOVER 2 at Week 16 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 at Week 24.

#P<0.0001 vs placebo.

ACR20 responses in DISCOVER 1 at Week 16 were not part of the sequential procedure but were prespecified to be tested upon achieving statistical significance for ACR20 at Week 24.

Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open-label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analysis from Weeks 24 to 52 is not shown.

References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 4. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial, Lancet. 2020;395(10230):1115-1125.